The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).
 
Yaewon Yang
No Relationships to Disclose
 
Eun Joo Kang
No Relationships to Disclose
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - PharmAbcine
Research Funding - Jeil Pharmaceutical Co
Travel, Accommodations, Expenses - ST Cube
 
Yu Jung Kim
No Relationships to Disclose
 
Sun Min Lim
Honoraria - Boehringer Ingelheim; Takeda; Yuhan
Research Funding - Janssen Research & Development
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Youngjoo Lee
Consulting or Advisory Role - MSD; Roche; Yuhan
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Ilhwan Kim
No Relationships to Disclose
 
Hee Kyung Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Boryung Pharmaceuticals; Bristol Myers Squibb; Celltrion; Daewoong Pharmaceutical; Daiichi-Sankyo; Eisai; Lilly; LSK Korea; MSD; Novartis; Pfizer; Sanofi/Aventis; Yuhan
Consulting or Advisory Role - Amgen; Gilead Sciences; Roche; Takeda
 
Soonil Lee
No Relationships to Disclose
 
So Yeon Oh
No Relationships to Disclose
 
Bae Woo Kyun
No Relationships to Disclose
 
Hyewon Ryu
No Relationships to Disclose
 
Kyong Hwa Park
Stock and Other Ownership Interests - iMBDx
Honoraria - Celltrion
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo
Patents, Royalties, Other Intellectual Property - IP transfer fee
Expert Testimony - LegoChem Biosciences
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck